Rocuronium Consumption in Etomidate-based and Propofol-based General Anesthesia Under Sevoflurane

Consumption of Rocuronium Under Etomidate-based Versus Propofol-based Maintenance of General Anesthesia Under Different Concentration of Sevoflurane- BIS Guided Clinical Trial in a Closed Loop Infusion System

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02711917

Enrollment

175

Registered

2016-03-17

Start date

2015-07-31

Completion date

2016-01-31

Last updated

2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuromuscular Monitoring

Keywords

Propofol, Sevoflurane, Etomidate, Rocuronium, BIS, Closed loop infusion system

Brief summary

Different concentration of sevoflurane was given to maintain anesthesia. The dose of propofol to maintain BIS between 40-60 and the consumption of rocuronium was recorded and evaluated.

Detailed description

2 age group of patients was selected, 40-60 years and above 60 years. Maintenance of anesthesia was carried out using different concentration of Sevoflurane, ie MAC 0.5, 0.75 and 1.0. Bis value was kept between 40-60 and the dose of propofol required was recorded. Rocuronium infusion given in a close loop infusion system for different group was tabulated. The results was then analysed.

Interventions

DRUGMAC 0.5

0.5 MAC Sevoflurane

DRUGMAC 0.75

0.75 MAC Sevoflurane

DRUGMAC 1.0

1.0 MAC Sevoflurane

DRUGPropofol

Propofol consumption

DRUGEtomidate

Etomidate consumption

DRUGRocuronium

Consumption of Rocuronium

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* BMI \< 30 * elective Gynaecological/abdominal/urological surgery * Operation time \< 3hrs * ASA I/II * Intubated patients

Exclusion criteria

* Coronary artery disease, cardiac, lung, hepatic and renal insufficiency * Severe uncontrolled HBP * Obesity (BMI \>30) * Neuromuscular and metabolic diseases * Receiving medication known to influence neuromuscular transmission * Pregnancy * Psychiatric disorders * Allergy history to any of the drugs that will be used

Design outcomes

Primary

Measure	Time frame	Description
consumption of propofol	Intraoperative	Propofol, Etomidate, Rocuronium consumption under specific concentration of sevoflurane keeping BIS between 40-60

Secondary

Measure	Time frame	Description
Recovery Index	Intraoperative	T25%-T75%
Onset time	Intraoperative	Time from starting infusion of Rocuronium at induction till T\<10%
Sevoflurane time	Intraoperative	Time from starting sevoflurane till end tidal concentration is reached

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026